By AMIE TSANGNOV. 3, 2016
Steady as she goes.The Federal Reserve (unsurprisingly) decided not to raise interest rates just days before an already contentious election. But it seemed eager to do so at its December meeting — and eager to signal its intent.It struck a more positive note than in September, highlighting that inflation had strengthened (but that it was still below its 2 percent target).A December rate rise is not a foregone conclusion, though, and the Fed has backed away before.You might ask, why all the indecision?Well, Fed officials have been like sailors trying to make headway in a windless sea, resorting to different measures to revive growth.AdvertisementNow, they have to raise rates without tipping over the boat.The Fed does not want to derail growth by raising rates too soon. But if they wait too long, they might have to lift rates sharply, risking a recession. We explain in more detail here.AdvertisementIf you’re keeping an eye on monetary policy in Britain, here’s what is expected from the Bank of England, whose governor announced he would stay at the central bank until mid-2019, despite political pressure for him to quit.Another day, another deal between chip makers.Broadcom has become the latest semiconductor manufacturer to join the rush to consolidate.Our columnist Andrew Ross Sorkin and his Times colleagues help you make sense of major business and policy headlines — and the power-brokers who shape them.Please verify you're not a robot by clicking the box.Invalid email address. Please re-enter.You must select a newsletter to subscribe to.View all New York Times newsletters.It has agreed to buy Brocade Communications Systems, which makes switches and networking equipment, for $5.5 billion. Broadcom, itself the product of a recent merger, said the deal would help it to provide better connections to data storage systems.More companies look to be joining in.Microsemi, another chip maker, has hired a bank to run an auction after Skyworks Solutions expressed an interest in taking over, according to a Bloomberg report that cited people familiar with the matter.Microsemi makes chips for use in defense, communications and aerospace. These products command higher prices and would help Skyworks become less reliant on the market for phones.And could we see a flurry of deals in the banking sector too?Breakingviews considers whether it is time for European banks to team up. It would be messy — just think about the regulatory issues and conflicts of interest — but it could be the way take on the competition over in the United States.While others are looking to merge, Valeant Pharmaceuticals seems to be turning away from its aggressive deal making in an effort to cut debt.AdvertisementAccording to The Wall Street Journal, which cited people familiar with the matter, the company is considering selling its eye-surgery equipment business, which could fetch as much as $2.5 billion. The Journal also reported that Valeant was in advanced talks to sell Salix Pharmaceuticals, its stomach drug unit, for $10 billion.Valeant is one of a number of pharmaceutical companies that have been scrutinized over aggressive pricing policies.Bloomberg took a look at how deal makers have turned to flipping pharmaceuticals. It involves buying licensing rights to a medicine, jacking up the price and putting the rights back on the market.“All-out legal war with Thiel would have cost too much, and hurt too many people, and there was no end in sight.”— Nick Denton, the founder of Gawker Media, on the decision to settle with Hulk Hogan for $31 million in a lawsuit financed by the Silicon Valley billionaire Peter Thiel.Follow Amie Tsang on Twitter @amietsang.We’re interested in your feedback on this page. Tell us what you think.